Niowave and Ratio Partner to Advance Actinium-225 Supply
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
SANTA CRUZ, Calif., March 16, 2026 Unnatural Products has announced the successful closing of a $45 million Series B...
BOSTON, Massachusetts — December 16, 2025 — CTT Pharmaceutical Holdings, Inc. (CTT Pharma) announced that its scientific team has...
Dateline — WALTHAM, Mass., November 11, 2025:Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing...
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
Andelyn Biosciences, a leading cell and gene therapy CDMO, has partnered with Tern Therapeutics to perform late-stage Process Performance...
